Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first-line platinum-based doublet chemotherapy stratified by Veristrat good versus Veristrat poor. The European thoracic oncology platform (ETOP) EMPHASIS-lung trial.
Authors
Peters, SStahel, R
Dafni, U
Ponce Aix, S
Massutí, B
Gautschi, O
Coate, L
López Martín, A
van Heemst, R
Berghmans, T
Meldgaard, P
Cobo Dols, M
Garde Noguera, J
Curioni-Fontecedro, A
Rauch, D
Mark, M
Cuffe, S
Biesma, B
van Henten, A
Juan Vidal, Ó
Palmero Sanchez, R
Villa Guzmán, J
Collado Martin, R
Peralta, S
Insa, A
Summers, Yvonne J
Láng, I
Horgan, A
Ciardiello, F
de Hosson, S
Pieterman, R
Groen, H
van den Berg, P
Zielinski, C
Chittazhathu Kurian Kuruvilla, Y
Gasca-Ruchti, A
Kassapian, M
Novello, S
Torri, V
Tsourti, Z
Gregorc, V
Smit, E
Affiliation
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.Issue Date
2016-12-23
Metadata
Show full item recordAbstract
Docetaxel and erlotinib are registered second-line treatments for wild-type EGFR NSCLC. Previous studies suggested a predictive value of the VeriStrat test in second-line therapy of NSCLC, classifying patients as either VeriStrat good or VeriStrat poor. EMPHASIS-lung aimed at exploring this predictive effect in patients with squamous cell NSCLC. The trial closed prematurely because of low accrual and results from other trials. Our analysis includes an exploratory combined analysis with results from the PROSE trial.Citation
Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first-line platinum-based doublet chemotherapy stratified by Veristrat good versus Veristrat poor. The European thoracic oncology platform (ETOP) EMPHASIS-lung trial. 2016, J Thorac OncolJournal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2016.12.017PubMed ID
28017787Type
ArticleLanguage
enISSN
1556-1380ae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2016.12.017
Scopus Count
Collections
Related articles
- Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
- Authors: Buttigliero C, Shepherd FA, Barlesi F, Schwartz B, Orlov S, Favaretto AG, Santoro A, Hirsh V, Ramlau R, Blackler AR, Roder J, Spigel D, Novello S, Akerley W, Scagliotti GV
- Issue date: 2019 Jun
- The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
- Authors: Lee SM, Upadhyay S, Lewanski C, Falk S, Skailes G, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Rudd R, Ngai Y, Edwards A, Hackshaw A
- Issue date: 2019 Oct
- Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
- Authors: Nishiyama A, Katakami N, Yoshioka H, Iwasaku M, Korogi Y, Hata A, Takeshita J, Otsuka K, Nishino K, Uchida J, Okuyama T, Namba Y, Mori M, Fujita S, Morita S
- Issue date: 2015 Sep
- Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
- Authors: Rulli E, Marabese M, Torri V, Farina G, Veronese S, Bettini A, Longo F, Moscetti L, Ganzinelli M, Lauricella C, Copreni E, Labianca R, Martelli O, Marsoni S, Broggini M, Garassino MC, TAILOR trialists
- Issue date: 2015 Oct
- Evaluation of the VeriStrat(®) serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.
- Authors: Gadgeel S, Goss G, Soria JC, Felip E, Georgoulias V, Lu S, Cobo M, Syrigos K, Lee KH, Göker E, Guclu SZ, Isla D, Morabito A, Dupuis N, Bühnemann C, Krämer N, Solca F, Ehrnrooth E, Ardizzoni A
- Issue date: 2017 Jul